Allogene Therapeutics
Van Le is a Senior QC Analyst at Allogene Therapeutics since October 2022, previously holding positions as QC Analyst II within the same company. Prior experience includes roles as Research Associate II at Adverum Biotechnologies, Inc. from February 2022 to July 2022, QC Research Associate at Advanced Cell Diagnostics from February 2021 to February 2022, and QC Scientist at Eurofins Lancaster Laboratories from September 2019 to February 2021. Van Le also worked as a Diagnostic Technician at Roche from January 2019 to September 2019, as a Laboratory Technician at Hycor Biomedical LLC in mid-2017, and as an Analytical Chemist at ABC Testing Inc. from February 2017 to May 2017. Educational background includes a Bachelor of Science in Biochemistry from California State University, Long Beach, and an Associate of Science in Biological Sciences from De Anza College.
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.